Poster Presentation The Annual Scientific Meeting of the Australian Diabetes Society and the Australian Diabetes Educators Association 2013

Changing from a glargine-based insulin regimen to biphasic insulin aspart 30 in people with type 2 diabetes (#327)

Zanariah Hussein 1 , Mohammad Khamseh 2 , Wenying Yang 3 , Siddharth Shah 4 , Jianwen Chen 5 , Leon Litwak 6 , Alana Philips 7
  1. Medical Department, Hospital Putrajaya, Putrajaya, Malaysia
  2. Institute of Endocrinology & Metabolism, Tehran University of Medical Sciences, Tehran, Iran
  3. Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China
  4. Department of Medicine/Diabetology, Bhatia Hospital, Mumbai, India
  5. Novo Nordisk A/S International Operations, Zurich, Switzerland
  6. Endocrinology, Metabolism and Nuclear Medicine, Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires, Argentina
  7. Novo Nordisk, Baulkham Hills, NSW, Australia

Objective: A subgroup analysis from the A1chieve study explored clinical outcomes in people with poorly-controlled type 2 diabetes (T2DM) changing from insulin glargine ± oral glucose-lowering drugs (OGLDs) to biphasic insulin aspart 30 ± OGLDs during routine clinical care.

Methods: A1chieve was a 24-week, non-interventional study evaluating the safety and effectiveness of insulin analogs in people with T2DM (n=66,726) in routine clinical care in 28 countries across four continents.

Results: Insulin dose increased by 64% in the 1395 people studied. Mean HbA1c at baseline was 9.7 % (SD 1.7 %) and reduced by 1.9 % (1.7 %) to 7.8 % (1.3 %) at 24 weeks. Other measures of glycemic control improved similarly, and 21.9% of patients achieved an HbA1c level <7.0 % compared to 3.3% at baseline, with reduced incidence of reported overall and major hypoglycemia (Table).

Conclusions: Changing from insulin glargine to biphasic insulin aspart 30 was associated with improvements in glycemic control, with reduced incidence of hypoglycemia and particularly notable improvements in postprandial glucose levels.  


Acknowledgments: Novo Nordisk